Strong growth

Becton Dickinson (or BD) (BDX) has seen tremendous growth in recent years, driven by some of its major acquisitions and key product launches. The company invested approximately 6.1% of its total revenues in R&D (research and development) in 3Q17.

How Innovation Is Driving Becton Dickinson’s Growth in 2017

Peers Thermo Fisher Scientific (TMO), Abbott Laboratories (ABT), and Medtronic (MDT) invested about 4.4%, 7.5%, and 7.4% of their total revenues in R&D, respectively, in their recently ended quarters. Investors can consider investing in the Vanguard Health Care ETF (VHT) for exposure to BD and its peers. VHT has approximately 1.3% of its total holdings in BD.

Life Sciences segment: New product innovations

The BD Max System, a molecular testing platform, is a key product among BD’s diagnostics offerings. The company is continuously investing in extending its capabilities and offering differentiated panels to its customers. The BD Max extended enteric bacterial panel is the third among its suite of four enteric series of panels. The last panel to be approved is a viral panel. This new molecular test was approved by the FDA (U.S. Food & Drug Administration) in June 2017. For more details, read Which BD Product Launches Will Drive the Most Growth?

In April 2017, BD received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system. The system is used with a leucocount reagent assay, which is used to count residual white blood cells in blood products.

Another major product innovation is Kiestra, BD’s urine culture application, which enables laboratory automation. The company continually adds various modules to its Keistra platform to enhance its capabilities. A recent enhancement is the use of BD Keistra with BD BBL plated media, which uses imaging to help discard no growth culture plates. Some of the installations of the application that were expected in the third quarter of 2017 are now expected to be realized in the fourth quarter.

BD medical: New product innovations

BD has launched some new enterprise software for its medication management solutions platforms Cato and Pharmogistics. The products have seen positive customer uptake.

As part of BD’s revenue synergy strategy, the company has launched a new infusion set for Asia. It plans to launch two infection prevention products every year going forward. In 2016, BD entered into an agreement with Fresenius Kabi for the supply of intravenous solutions. The company has since been working with Fresenius to bring a broad portfolio of intravenous solutions to the market in the United States.

In the next part of this series, we’ll look at the company’s updated guidance for 4Q17 and 2017.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.